February 17, 2016 – Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced that it filed a Marketing Authorization Application with the European Medicines Agency (EMA) for EP4 antagonist (Galliprant®/grapiprant/ RQ-00000007/AT-001, hereinafter called “Galliprant”)